The U.S. Food and Drug Administration has granted orphan drug status to cabozantinib for the treatment of hepatocellular carcinoma, the most common type of liver cancer.
Liver cancer
Scientists have long believed that liver cancer cells needed fat molecules to survive, and that by blocking fat production, the cancer would starve. But a new Australian…
Focused ultrasound appears to be able to selectively destroy liver tumors, new research from an EU project shows. Preliminary results of this new method, developed…
Combining the chemotherapy agent Sutent (sunitinib) and immunotherapy may be a promising strategy to fight hepatocellular carcinoma, the most common type of liver cancer, according…
News
Tivantinib Provides No Survival Benefit in Hepatocellular Carcinoma Patients, Phase 3 Study Shows
Tivantinib, an experimental oral inhibitor of the MET receptor, is not better than best supportive care in patients with inoperable hepatocellular carcinoma (HCC) who are intolerant or…
Recent Posts
- Alagille Syndrome Awareness Day seeks to unite global community
- Long-term trial results raise hopes for new hepatitis D treatment approach
- Genetic analysis unveils 3 potentially key treatment targets for PSC
- Getting ahead of concerns about fatty liver disease in children
- Early trial results testing maralixibat for hard-to-treat itching due by year’s end